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The risk of developing invasive EOC is higher than the population average for relatives of women diagnosed with the disease 1,2 , indicating the importance of genetic factors in disease susceptibility. Approximately 25% of the familial aggregation of EOC is explained by rare, high-penetrance alleles of BRCA1 and BRCA2 (ref. 3 ). Furthermore, population-based GWAS have identified common variants associated with invasive EOC at 11 loci [4] [5] [6] [7] [8] [9] , but only 6 have also been evaluated in BRCA1 and/or BRCA2 mutation carriers. All loci analyzed displayed associations in mutation carriers that were consistent with the associations observed in the general population 10-12 . In addition, the 4q32.3 locus is associated with EOC risk for BRCA1 mutation carriers only 13 . However, the common genetic variants identified explain less than 3.1% of the excess familial risk of EOC, so additional susceptibility loci are likely to exist.
Women diagnosed with EOC and unaffected women from the general population ascertained through the Ovarian Cancer Association Consortium (OCAC) 14 and BRCA1 and BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) 15 were genotyped as part of the Collaborative Oncological Gene-environment Study (COGS) using the iCOGS custom array. In addition, data were available for cases and controls from three EOC GWAS. We first evaluated whether the EOC susceptibility loci at 8q21.13, 10p12.31, 17q12, 5p15.33 and 17q21.31 recently identified by OCAC [7] [8] [9] also showed evidence of association in BRCA1 and BRCA2 mutation carriers. Using data from >200,000 genotyped SNPs 7, 13, 16 , we performed imputation of common variants from 1000 Genomes Project data 17 and evaluated the associations of these SNPs with invasive EOC risk in OCAC samples and in BRCA1 and BRCA2 mutation carriers from CIMBA. Given the strong evidence for a significant overlap in loci predisposing to EOC in the general population and those associated with risk in BRCA1 and BRCA2 mutation carriers, we carried out a meta-analysis of the EOC risk associations to identify new EOC susceptibility loci.
Genotype data were available for imputation on 15,252 BRCA1 mutation carriers and 8,211 BRCA2 mutation carriers, of whom 2,462 and 631, respectively, were affected with EOC 13, 16 . For OCAC samples, genotyping data were available from 15,437 women with invasive EOC (including 9,627 with serous EOC) and 30,845 controls from the general population 7 . Imputation was performed separately for BRCA1 mutation carriers, BRCA2 mutation carriers, OCAC-COGS samples and samples included in the three OCAC GWAS ( Supplementary  Figs. 1 and 2, and Supplementary Tables 1 and 2) . The meta-analysis was based on data for 11,403,952 SNPs (Supplementary Fig. 3) .
Of the five EOC susceptibility loci that had not yet been evaluated in mutation carriers, two were associated with EOC risk for both BRCA1 and BRCA2 mutation carriers at P < 0.05 (10p12. 31 and 17q21.31) ( Supplementary Table 3 ). Overall, 7 of the 12 known EOC susceptibility loci provided evidence of association in BRCA1 mutation carriers and 6 were associated in BRCA2 mutation carriers. With the exception of 5p15.33 (TERT), all loci had hazard ratio (HR) estimates in BRCA1 and BRCA2 mutation carriers that were in the same direction as the odds ratio (OR) estimates for the serous subtype EOC samples in OCAC ( Fig. 1) . Analyzing the associations jointly in BRCA1 and BRCA2 mutation carriers and serous EOC cases in OCAC provided stronger evidence of association, with smaller P values for eight of the susceptibility variants in comparison to the analysis in OCAC samples alone.
Using the imputed genotypes, we observed no new associations at P < 5 × 10 −8 in the analysis of associations in BRCA1 and BRCA2 mutation carriers separately. However, we identified seven previously unreported associations (P < 5 × 10 −8 ) in OCAC samples alone, in the meta-analysis of EOC associations in BRCA1 and BRCA2 mutation carriers and OCAC samples, or in the meta-analysis in BRCA1 and BRCA2 mutation carriers and serous EOC cases from OCAC ( Supplementary Fig. 4 and Supplementary Tables 4 and 5). SNPs in six of these loci remained genome-wide statistically significant after we reimputed genotypes with imputation parameters set to maximize accuracy ( Fig. 1 and Table 1 ). We found SNPs at 17q11.2 (near ATAD5) to be associated with invasive EOC in the OCAC samples (P < 5 × 10 −8 ) ( Table 1) . For the lead SNP, chr17:29181220:I, the estimated HR value for BRCA1 mutation carriers was significantly different from the estimate in OCAC samples (P = 0.005); the association for BRCA2 mutation carriers was consistent with the OCAC OR estimate (BRCA2-OCAC meta-analysis P = 2.6 × 10 −9 ). SNPs at four loci were associated at P < 5 × 10 −8 with risk of all invasive EOC subtypes in the meta-analysis ( Supplementary Fig. 5 ): 1p36, 1p34.3, 4q26 and 9q34.2. At 1p34.3, the most strongly associated SNP, rs58722170, displayed stronger associations in the meta-analysis of serous EOC cases from OCAC (P = 2.7 × 10 −12 ). In addition, SNPs at 6p22.1 were associated at a genome-wide significance level in the meta-analysis of associations with serous EOC (P = 3.0 × 10 −8 ) but not in the meta-analysis of all invasive EOC associations (P = 6.8 × 10 −6 ).
The most significantly associated SNP at each of the six new loci had high imputation accuracy (r 2 ≥ 0.83). At the 1p34.3, 1p36 and 6p22.1 loci, there was at least one genome-wide significant genotyped SNP correlated with the lead SNP (pairwise r 2 ≥ 0.73) ( Supplementary Fig. 5 , Supplementary Table 6 and Supplementary Note). We genotyped the leading (imputed) SNPs of the three other loci in a subset of the samples using iPLEX technology (Supplementary Note). Correlations between the expected allele dosages from imputation and the observed genotypes for the variants at 4q26 and 9q34.2 (r 2 = 0.90 and 0.84, respectively) were consistent with the estimated imputation accuracy scores (0.93 and 0.83 for CIMBA samples). The lead SNP at 17q11.2 failed iPLEX design. However, the risk-associated allele was highly correlated with the AA haplotype of two genotyped variants on the iCOGS array (rs9910051 and rs3764419). This haplotype was strongly associated with ovarian cancer risk in the subset of samples genotyped using the iCOGS array (BRCA2-OCAC meta-analysis P = 8.6 × 10 −8 for this haplotype and P = 1.8 × 10 −8 for chr17:29181220:I) (Supplementary Table 7 ).
None of the regions contained additional SNPs that displayed EOC associations at P < 1 × 10 −4 in OCAC samples, BRCA1 mutation carriers or BRCA2 mutation carriers in multi-variable analyses adjusted Table 2) . We carried out a competing risks association analysis in BRCA1 and BRCA2 mutation carriers to investigate whether these loci were also associated with breast cancer risk for mutation carriers (Supplementary Note). We used the most strongly associated genotyped SNPs for this purpose because the statistical method required actual genotypes 18 . The HR estimates for EOC were consistent with the estimates from the main analysis for all SNPs (Supplementary Table 8 ). None of the SNPs displayed associations with breast cancer risk at P < 0.05.
At each of the six loci, we identified a set of SNPs with odds of less than 100 to 1 against them being the causal variant; most were in noncoding DNA regions ( Supplementary Table 9 ). None were predicted to have likely deleterious functional effects, although some were in or near chromatin biofeatures in fallopian tube and ovarian epithelial cells, which might represent the functional regulatory targets of the risk-associated SNPs ( Table 3 and Supplementary Table 10 ). We also evaluated the protein-coding genes in each region for their role in EOC development and as candidate susceptibility gene targets. Molecular profiling data from 496 high-grade serous ovarian cancers (HGSOCs) collected by The Cancer Genome Atlas (TCGA) indicated frequent loss or deletion at 4 risk loci (1p36, 4q26, 9q34.2 and 17q11.2) ( Supplementary Table 11 ). Consistent with this observation, the expression of WNT4, SYNPO2 and ABO was significantly downregulated in ovarian tumors, whereas ATAD5 expression was upregulated (P < 6 × 10 −5 , HuEx platform). Somatic coding-sequence mutations in the six genes nearest the index SNPs were rare. We performed expression quantitative trait locus (eQTL) analysis in a series of 59 normal ovarian tissues ( Supplementary Table 12 ) to evaluate the gene nearest the top ranked SNP at each locus. For the five genes expressed in normal cells, we found no statistically significant eQTL associations for any of the putative causal SNPs at each locus; neither did we find any significant tumor-eQTL associations for these genes based on data from TCGA ( Supplementary Table 12 ). At the 1p36 locus, the most strongly associated variant, rs56318008, was located npg l e t t e r s in the promoter region of WNT4, which encodes a ligand in the WNT signal transduction pathway, critical for cell proliferation and differentiation. Using a luciferase reporter assay, we found no effect of these putatively causal SNPs on WNT4 transcription in iOSE4 normal ovarian cells (Fig. 2) . Some of the putative causal SNPs at 1p36 were located in CDC42 and LINC00339, and several were in putative regulatory domains in ovarian tissues ( Fig. 2 and Supplementary  Table 10 ). CDC42 is known to have a role in migration and signaling in ovarian and breast cancers 19, 20 . SNPs at 1p36 are also associated with increased risk of endometriosis, and WNT4, CDC42 and LINC00339 have all been implicated in endometriosis 21 , a known risk factor for endometrioid and clear cell EOCs 22 . The strongest associated variant at 1q34, rs58722170, was located in RSPO1, which encodes R-spondin 1, a protein involved in cell proliferation ( Supplementary Fig. 6 ). RSPO1 is important in tumorigenesis and early ovarian development 23, 24 , and it regulates WNT4 expression in the ovaries 25 . SYNPO2 at 4q26 encodes myopodin, which is involved in cell motility and growth 26 and has a reported tumorsuppressor role [27] [28] [29] [30] . rs635634 is located upstream of the ABO gene ( Supplementary Fig. 7) . A moderately correlated variant (rs505922; r 2 = 0.52) determines ABO blood group and is associated with increased risk of pancreatic cancer 31, 32 . Previous studies in OCAC also showed a modestly increased risk of EOC for individuals with the A blood group 33 . The moderate correlation between rs635634 and rs505922 and the considerably weaker EOC association of rs505922 (P = 1.2 × 10 −5 ) suggest that the association with blood group is probably not driving the risk association. The indel chr17:29181220:I at 17q11.2 is located in ATAD5, which acts as a tumor-suppressor gene [34] [35] [36] (Supplementary Fig. 8 ). ATAD5 protein modulates the interaction between RAD9A and BCL2 to induce DNA damagerelated apoptosis. Finally, rs116133110, at 6p22.1, lies in GPX6, which has no known role in cancer.
The 6 new loci reported in this study increase the number of genome-wide significant common variant loci so far identified for EOC to 18. Taken together, these loci explain approximately 3.9% of the excess familial relative risk of EOC in the general population and account for approximately 5.2% of the polygenic modifying variance for EOC in BRCA1 mutation carriers and 9.3% of the variance in BRCA2 mutation carriers. The similarity in the magnitude of the associations between BRCA1 and BRCA2 mutation carriers and cases from population-based studies suggests a general model of susceptibility whereby BRCA1 and BRCA2 mutations and common alleles interact multiplicatively on the relative risk scale for EOC 37 . This model predicts large differences in absolute EOC risk between individuals carrying many risk-associated alleles and individuals carrying few alleles for EOC susceptibility in BRCA1 and BRCA2 mutation carriers 13, 16 . Incorporating EOC susceptibility variants into risk assessment tools will improve risk prediction and might be particularly useful for BRCA1 and BRCA2 mutation carriers. 
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Confirmatory genotyping of imputed SNPs.
To evaluate the accuracy of imputation for the SNPs we found to be associated with EOC risk, we genotyped rs17329882 (4q26) and rs635634 (9q34.2) in a subset of 3,541 subjects from CIMBA using Sequenon's iPLEX technology. The lead SNP at 17q11.2, chr17:29181220:I, failed iPLEX design. We performed quality control of the iPLEX data according to CIMBA guidelines. After quality control, we used the imputation results to generate the expected allele dosage for each genotyped sample and computed the Pearson product-moment correlation coefficient between the expected allele dosage and the observed genotype. The squared correlation coefficient was compared to the imputation accuracy as estimated from the imputation.
Quality control of GWAS and iCOGS genotyping data.
We carried out quality control separately for BRCA1 mutation carriers, BRCA2 mutation carriers, the three OCAC GWAS and the OCAC-iCOGS samples, but quality criteria were mostly consistent across studies. We excluded samples if they were not of European ancestry, if they had a genotyping call rate of <95%, if they showed low or high heterozygosity, if they were not female or had ambiguous sex or if they were duplicates (cryptic or intended). In the OCAC studies, one individual was excluded from each pair of samples found to be first-degree relatives, and duplicate samples between the iCOGS stage and any of the GWAS were excluded from the iCOGS data. SNPs were excluded if they were monomorphic, had a call rate of < 95%, showed evidence of deviation from Hardy-Weinberg equilibrium or had low concordance between duplicate pairs. For the Mayo GWAS and the UK GWAS, we also excluded rare SNPs (MAF < 1% or allele count < 5, respectively). We visually inspected genotype cluster plots for all SNPs with association P < 1 × 10 −5 from each of the newly identified loci. We used the R GenABEL library version 1.6.7 for quality control. Genotype data were available for analysis from iCOGS for 199,526 SNPs in OCAC-iCOGS samples, 200,720 SNPs in BRCA1 mutation carriers and 200,908 SNPs in BRCA2 mutation carriers. After quality control, for the GWAS, data were available on 492,956 SNPs for the US GWAS, 543,529 SNPs for the UK GWAS and 1,587,051 SNPs for the Mayo GWAS (Supplementary Table 2 ). Imputation. We performed imputation separately for BRCA1 mutation carriers, BRCA2 mutation carriers, OCAC-iCOGS samples and each of the OCAC GWAS. We imputed variants from 1000 Genomes Project data using the v3 April 2012 release 17 as the reference panel. For OCAC-iCOGS samples, the UK GWAS and the Mayo GWAS, imputation was based on the 1000 Genomes Project data with singleton sites removed. To improve computation efficiency, we initially used a two-step procedure, which involved pre-phasing in the first step and imputation of the phased data in the second step. We carried out pre-phasing using SHAPEIT software 40 . We used IMPUTE version 2 software for the subsequent imputation 41 for all studies with the exception of the US GWAS, for which the MACH algorithm implemented in Minimac software version 2012.8.15, MACH version 1.0.18, was used. To perform imputation, we divided the data into segments of approximately 5 Mb each. We excluded SNPs from the association analysis if their imputation accuracy was r 2 < 0.3, their MAF was <0.005 in BRCA1 or BRCA2 mutation carriers or their accuracy was r 2 < 0.25 in OCAC-iCOGS samples, the UK GWAS, the US GWAS or the Mayo GWAS.
We performed more accurate imputation for the regions around the new EOC loci from the joint analysis of the data from BRCA1 and BRCA2 mutation carriers and the general population (any SNP with association P < 5 × 10 −8 ). The boundaries of these regions were set 500 kb away from any significantly associated SNP in the region. As in the first run, 1000 Genomes Project data v3 were used as the reference panel, and IMPUTE2 software was applied. However, for the second round of imputation, we imputed genotypes without pre-phasing to improve accuracy. To further increase imputation accuracy, we changed some of the default parameters in the imputation procedure. These included an increase in the MCMC iterations to 90 (out of which the first 15 were used as burn-in), an increase in the buffer region to 500 kb and an increase in the number of haplotypes used as templates when phasing observed genotypes to 100. These changes were applied consistently for all data sets.
Statistical analyses.
Association analyses in the unselected ovarian cancer cases and controls from OCAC. We evaluated the association between genotype and disease using logistic regression by estimating the associations with each additional copy of the minor allele (log-additive models). The analysis was adjusted for study and for population substructure by including the eigenvectors of the first five ancestry-specific principal components as covariates in the model. We used the same approach to evaluate SNP associations with serous ovarian cancer after excluding all cases with any other or unknown tumor subtype. For imputed SNPs, we used expected dosages in the logistic regression model to estimate SNP effect sizes and P values. We carried out analyses separately for OCAC-iCOGS samples and the three GWAS and pooled data thereafter using a fixed-effects meta-analysis. We carried out the analysis of reimputed genotypes for putative new susceptibility loci jointly for the OCAC-iCOGS samples and the GWAS samples. All results are based on the combined data from iCOGS and the three GWAS. We used custom written software for the analysis.
Associations in BRCA1 and BRCA2 mutation carriers from CIMBA. We carried out the ovarian cancer association analyses separately for BRCA1 and BRCA2 mutation carriers. The primary analysis was carried out within a survival analysis framework, with time to ovarian cancer diagnosis as the endpoint. Mutation carriers were followed until the age of ovarian cancer diagnosis or risk-reducing salpingo-oophorectomy (RRSO) or to the age at last observation. Breast cancer diagnosis was not considered to be a censoring event. To account for the non-random sampling of BRCA1 and BRCA2 mutation carriers with respect to their disease status, we conducted the analyses by modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotype 18 . We assessed the associations between genotype and risk of ovarian cancer using the 1-degree-of-freedom score test statistic based on retrospective likelihood 18, 42 . To account for the non-independence among related individuals in the sample, we used an adjusted version of the score test statistic, which uses a kinship-adjusted variance of the score 43 . We evaluated associations between imputed genotypes and ovarian cancer risk using a version of the score test as described above but with the posterior genotype probabilities replacing the genotypes. All analyses were stratified by the country of origin of the samples.
We carried out retrospective likelihood analyses in CIMBA using custom written functions in Fortran and Python. The score test statistic was implemented in R version 3.0.1 (ref. 44) .
We evaluated whether there was evidence for multiple independent association signals in the region around each newly identified locus by evaluating the associations of genetic variants in the region while adjusting for the SNP with the smallest meta-analysis P value in the respective region. This was done separately for BRCA1 mutation carriers, BRCA2 mutation carriers and OCAC samples.
For one of the new associations, it was not possible to confirm the imputation accuracy of the lead SNP chr17:29181220:I at 17q11.2 through genotyping. Therefore, we inferred two-allele haplotypes for rs9910051 and rs3764419, highly correlated with the lead SNP (r 2 = 0.95), using an in-house program. These variants were genotyped on the iCOGS array, and this analysis was therefore restricted to 14,733 ovarian cancer cases and 9,165 controls from OCAC-COGS and 8,185 BRCA2 mutation carriers for whom genotypes were available for both variants based on iCOGS. The association between the AA haplotype and risk was tested using logistic regression in OCAC samples and using Cox regression in BRCA2 mutation carriers.
Meta-analysis. We conducted a meta-analysis of the EOC associations in BRCA1 mutation carriers, BRCA2 mutation carriers and the general population for genotyped and imputed SNPs using an inverse variance approach assuming fixed effects. We combined the logarithm of the per-allele HR estimate for the association with EOC risk in BRCA1 and BRCA2 mutation carriers and the logarithm of the per-allele OR estimate for the association with disease status in OCAC. For associations in BRCA1 and BRCA2 carriers, we used the kinship-adjusted variance estimator 43 , which allows for the inclusion of related individuals in the analysis. We only used SNPs with results in OCAC and in at least one of the BRCA1 or the BRCA2 analyses. We carried out two separate meta-analyses, one for the associations with EOC in BRCA1 mutation carriers, BRCA2 mutation carriers and EOC samples in OCAC, irrespective of tumor histological subtype, and a second using only the associations with serous EOC in OCAC samples. The number of BRCA1 and BRCA2 mutation carriers with tumor histology information was too small to allow for subgroup analyses. However, previous studies have demonstrated that the majority of EOCs in BRCA1 and BRCA2 mutation carriers are high-grade serous [45] [46] [47] [48] [49] . Meta-analyses were carried out using Metal software, 2011-03-25 release 50 .
Candidate causal SNPs in each susceptibility region.
To identify a set of potentially causal variants, we excluded SNPs with a likelihood of being causal of less than 1:100, by comparing the likelihood of each SNP from the association analysis with the likelihood of the most strongly associated SNPs 51 . The remaining variants were then analyzed using Pupasuite 3.1 to identify potentially functional variants 52, 53 ( Supplementary Table 9 ).
Functional analysis. Expression quantitative trait locus analysis in normal ovarian and fallopian tube cells.
Early-passage primary normal ovarian surface epithelial cells (OSECs) and fallopian tube epithelial cells were collected from disease-free ovaries and fallopian tubes. Normal ovarian epithelial cells were collected by brushing the surface of the ovary with a sterile cytobrush and were cultured in NOSE-CM 54 . Fallopian tube epithelial cells were collected by Pronase digestion as previously described 55 , plated onto collagen-coated plastics (Sigma) and cultured in DMEM/F12 (Sigma-Aldrich) supplemented with 2% Ultroser G (BioSepra) and 1× penicillin-streptomycin (Lonza). By the time of RNA isolation, the fallopian tube cultures tested consisted of PAX8-positive fallopian tube secretory epithelial cells (FTSECs), consistent with previous observations that ciliated epithelial cells from the fallopian tube do not proliferate in vitro. Cell lines were routinely tested for mycoplasma.
For gene expression analysis, RNA was isolated from 59 early-passage samples: 54 OSECs and 5 FTSECs from cell cultures collected at ~80% confluency using the Qiagen miRNAeasy kit with on-column DNase I digestion. RNA (500 ng) was reverse transcribed using the Superscript III kit (Life Technologies). We preamplified 10 ng of cDNA using TaqMan Preamp Mastermix; the resulting product was diluted 1:60 and used to quantify gene expression with the following TaqMan gene expression probes: WNT4, Hs01573504_m1; RSPO1, Hs00543475_m1; SYNPO2, Hs00326493_m1; ATAD5, Hs00227495_m1; and GPX6, Hs00699698_m1. Four control genes were also included: ACTB, Hs00357333_g1; GAPDH, Hs02758991_g1; HMBS, Hs00609293_g1; and HPRT1, Hs02800695_m1 (all Life Technologies). Assays were run on an ABI 7900HT Fast Real-Time PCR system (Life Technologies).
Data analysis. Expression levels for each gene were normalized to the average of all four control genes. Relative expression levels were calculated using the ∆∆C t method. Genotyping was performed on the iCOGS chips, as described above. Where genotyping data were not available for the most risk-associated SNP, the next most significant SNP was used: rs3820282 at 1p36, rs12023270 at 1p34.3, rs752097 at 4q26, rs445870 at 6p22.1, rs505922 at 9q34.2 and rs3764419 at 17q11.2. Correlations between genotype and gene expression were calculated in R. Genotype-specific gene expression in normal tissue cell lines (eQTL analysis) was compared using the Jonckheere-Terpstra test. Data were normalized to the four control genes, and we tested for eQTL associations, grouping OSECs and FTSECs together. Second, OSECs were analyzed alone. eQTL analyses were performed using three genotype groups or two groups (with the rare homozygote samples grouped together with the heterozygote samples). eQTL analysis in primary ovarian tumors. eQTL analysis in primary tumors was based on publicly available data from the TCGA Project, which included 489 primary HGSOCs. The methods have been described elsewhere 56 . Briefly, we determined the ancestry for each case on the basis of germline genotype data using EIGENSTRAT software with 415 HapMap genotype profiles as a control set. Only populations of northern and western European ancestry were included. We first performed a cis-eQTL analyses using a method we described previously, in which the association between 906,600 germline genotypes and the expression levels of mRNA or miRNA (located within 500 kb on either side of the variant) were evaluated using a linear regression model with the effects of somatic copy number and CpG methylation being deducted. (For miRNA expression, the effect of CpG methylation was not adjusted for because these data were not available.) To correct for multiple tests, we adjusted the test P values using the Benjamini-Hochberg method. A significant association was defined by a false discovery rate (FDR) of <0.1.
Having established genome-wide cis-eQTL associations in this series of tumors, we then evaluated cis-eQTL associations for the top risk associations between each of the six new loci and the gene in closest proximity to the risk SNP. For each risk locus, we retrieved the genotype of all SNPs in ovarian cancer cases on the basis of the Affymetrix 6.0 array. Using these genotypes and the IMPUTE2 March 2012 1000 Genomes Project Phase I integrated variant cosmopolitan reference panel of 1,092 individuals (haplotypes were phased via SHAPEIT), we imputed the genotypes of SNPs in the 1000 Genomes Project in the target regions for TCGA samples 57 . For each risk locus where data for the most riskassociated variant were not available, we retrieved the imputed variants tightly correlated with the most risk-associated variant. We then tested for association between imputed SNPs and gene expression using the linear regression algorithm described above, where each imputed SNP was coded as an expected allele count. Again, significant associations were defined by an FDR of <0.1.
Regulatory profiling of normal ovarian cancer precursor tissues. We performed genome-wide FAIRE and chromatin immunoprecipitation with sequencing (ChIP-seq) for H3K27ac and H3K4me in two normal OSECs, two normal FTSECs and two HGSOC cell lines (UWB1.289 and CAOV3) (S.C., H.S., D.H., K.L. and K.B.K. et al., unpublished data). Cell lines were routinely tested for mycoplasma. These data sets annotate the epigenetic signatures of open chromatin and collectively indicate transcriptional enhancer regions. We analyzed the FAIRE-seq and ChIP-seq data sets and publically available genomic data on promoter and UTR domains, intron-exon boundaries and the positions of noncoding RNA transcripts to identify SNPs from the 100:1 likely causal set that aligned with biofeatures that might provide evidence of SNP functionality.
Candidate gene analysis using genome-wide profiling of primary ovarian cancers. Data sets: the TCGA Project and COSMIC data sets. TCGA has performed extensive genomic analysis of tumors from a large number of tissue types, including almost 500 high-grade serous ovarian tumors. These data include somatic mutations, DNA copy number, mRNA and miRNA expression, and DNA methylation. COSMIC is the catalog of somatic mutations in cancer that collates information on mutations in tumors from the published literature 58 . They have also identified the Cancer Gene Census, which is a list of genes known to be involved in cancer. Data are available on a large number of tissue types, including 2,809 epithelial ovarian tumors.
Somatic coding sequence mutations. We analyzed all genes for coding somatic sequence mutations generated from either whole-exome or whole-genome sequencing. In TCGA, whole-exome sequencing data were available for 316 high-grade serous EOC cases. In addition, we determined whether mutations had been reported in COSMIC 58 and whether the gene was a known cancer gene in the Sanger Cancer Gene Census. 
